Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for...
May 29, 2020 08:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

Dosing has progressed through first five cohorts up to 4 mg/kg dose levelStrong safety profile, with no dose-limiting toxicities observedMonotherapy activity (1 CR and 1 PR) observed in DLBCL...
May 15, 2020 17:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
May 13, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
May 06, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces “At-The-Market” Equity Program

CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
April 08, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

First patients in the 1.4 mg/kg cohort of TTI-621 and the 8.0 mg/kg cohort of TTI-622 clinical studies have been dosed. Going forward, expect a slow-down or potentially a pause in enrollment of new...
March 10, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Annual Financial and Operating Results

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
February 28, 2020 12:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Responds to Market Activity

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL)...
February 07, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Changes to Its Board of Directors

Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”)...
January 29, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...